CLIN CANCER RES：Veliparib联合托泊替康治疗实体肿瘤

2018-02-26 MedSci MedSci原创

CLIN CANCER RES近期发表了一篇文章，研究Veliparib联合托泊替康治疗实体肿瘤患者的剂量限制毒性（DLT），最大耐受剂量（MTD）和推荐Ⅱ期试验剂量（RP2D）。相关研究包括托泊替康和Veliparib对外周血单核细胞ADP核糖的影响，两种药物的血浆药代动力学以及基因突变和临床结局之间可能的关系。

CLIN CANCER RES近期发表了一篇文章，研究Veliparib联合托泊替康治疗实体肿瘤患者的剂量限制毒性（DLT），最大耐受剂量（MTD）和推荐Ⅱ期试验剂量（RP2D）。相关研究包括托泊替康和Veliparib对外周血单核细胞ADP核糖的影响，两种药物的血浆药代动力学以及基因突变和临床结局之间可能的关系。

研究纳入转移性非血液学恶性肿瘤的患者，病情可以进行评估。使用3+3设计，患者在1-3天，8-10天和15-17天每天2次口服Veliparib，在第2天，第9天和第16天静脉输入托泊替康，28天为1个周期。使用RECIST标准评估肿瘤反应。最终纳入58例患者，51例可以进行主要研究终点评估。MTD和RP2D为1-3天，8-10天和15-17天Veliparib 300mg，每天2次联合第2天，第9天和第16天托泊替康3mg/m2.DLT是持续时间＞5天的4级中性粒细胞减少。中位治疗周期数为2.客观反映率为10%，1例完全反应，4例部分反应。22例患者在4-26周期出现病情稳定。BRCA1，BRCA2或RAD51D突变的患者比无同源重组修复基因突变的患者进行研究的时间更长。

文章最后认为，托泊替康联合Veliparib安全性可控，需要进行进一步的研究。

原始出处：

Andrea E.Wahner Hendrickson,Michael E.Menefee,et al.A Phase ⅠClinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.CLIN CANCER RES.February 2018 doi:10.1158/1078-0432.CCR-17-1590

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1973230, encodeId=339119e3230d5, content=<a href='/topic/show?id=42cf546e792' target=_blank style='color:#2F92EE;'>#托泊替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54677, encryptionId=42cf546e792, topicName=托泊替康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Mon Jul 02 20:24:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292149, encodeId=12e8292149ff, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 02 06:25:09 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291817, encodeId=83de29181ea3, content=学习了.好文章., beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Mar 01 00:07:19 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361235, encodeId=808a136123524, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18366, encryptionId=1b63183668f, topicName=Veliparib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Feb 28 07:24:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379152, encodeId=311e13e9152d5, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Wed Feb 28 07:24:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291500, encodeId=d7232915007e, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Feb 28 00:08:40 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291126, encodeId=64d22911267f, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Feb 26 17:04:28 CST 2018, time=2018-02-26, status=1, ipAttribution=)]
2018-07-02 肉我只吃一口

#托泊替康#

39 0
[GetPortalCommentsPageByObjectIdResponse(id=1973230, encodeId=339119e3230d5, content=<a href='/topic/show?id=42cf546e792' target=_blank style='color:#2F92EE;'>#托泊替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54677, encryptionId=42cf546e792, topicName=托泊替康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Mon Jul 02 20:24:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292149, encodeId=12e8292149ff, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 02 06:25:09 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291817, encodeId=83de29181ea3, content=学习了.好文章., beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Mar 01 00:07:19 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361235, encodeId=808a136123524, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18366, encryptionId=1b63183668f, topicName=Veliparib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Feb 28 07:24:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379152, encodeId=311e13e9152d5, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Wed Feb 28 07:24:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291500, encodeId=d7232915007e, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Feb 28 00:08:40 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291126, encodeId=64d22911267f, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Feb 26 17:04:28 CST 2018, time=2018-02-26, status=1, ipAttribution=)]
2018-03-02 1e0f8808m18(暂无匿称)

学习了.谢谢分享.

52 0
[GetPortalCommentsPageByObjectIdResponse(id=1973230, encodeId=339119e3230d5, content=<a href='/topic/show?id=42cf546e792' target=_blank style='color:#2F92EE;'>#托泊替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54677, encryptionId=42cf546e792, topicName=托泊替康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Mon Jul 02 20:24:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292149, encodeId=12e8292149ff, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 02 06:25:09 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291817, encodeId=83de29181ea3, content=学习了.好文章., beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Mar 01 00:07:19 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361235, encodeId=808a136123524, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18366, encryptionId=1b63183668f, topicName=Veliparib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Feb 28 07:24:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379152, encodeId=311e13e9152d5, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Wed Feb 28 07:24:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291500, encodeId=d7232915007e, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Feb 28 00:08:40 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291126, encodeId=64d22911267f, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Feb 26 17:04:28 CST 2018, time=2018-02-26, status=1, ipAttribution=)]
2018-03-01 1e0f8808m18(暂无匿称)

学习了.好文章.

55 0
[GetPortalCommentsPageByObjectIdResponse(id=1973230, encodeId=339119e3230d5, content=<a href='/topic/show?id=42cf546e792' target=_blank style='color:#2F92EE;'>#托泊替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54677, encryptionId=42cf546e792, topicName=托泊替康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Mon Jul 02 20:24:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292149, encodeId=12e8292149ff, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 02 06:25:09 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291817, encodeId=83de29181ea3, content=学习了.好文章., beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Mar 01 00:07:19 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361235, encodeId=808a136123524, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18366, encryptionId=1b63183668f, topicName=Veliparib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Feb 28 07:24:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379152, encodeId=311e13e9152d5, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Wed Feb 28 07:24:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291500, encodeId=d7232915007e, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Feb 28 00:08:40 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291126, encodeId=64d22911267f, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Feb 26 17:04:28 CST 2018, time=2018-02-26, status=1, ipAttribution=)]
2018-02-28 jiangfeng5067

#Veliparib#

37 0
[GetPortalCommentsPageByObjectIdResponse(id=1973230, encodeId=339119e3230d5, content=<a href='/topic/show?id=42cf546e792' target=_blank style='color:#2F92EE;'>#托泊替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54677, encryptionId=42cf546e792, topicName=托泊替康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Mon Jul 02 20:24:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292149, encodeId=12e8292149ff, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 02 06:25:09 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291817, encodeId=83de29181ea3, content=学习了.好文章., beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Mar 01 00:07:19 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361235, encodeId=808a136123524, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18366, encryptionId=1b63183668f, topicName=Veliparib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Feb 28 07:24:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379152, encodeId=311e13e9152d5, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Wed Feb 28 07:24:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291500, encodeId=d7232915007e, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Feb 28 00:08:40 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291126, encodeId=64d22911267f, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Feb 26 17:04:28 CST 2018, time=2018-02-26, status=1, ipAttribution=)]
2018-02-28 weiz

#实体肿瘤#

35 0
[GetPortalCommentsPageByObjectIdResponse(id=1973230, encodeId=339119e3230d5, content=<a href='/topic/show?id=42cf546e792' target=_blank style='color:#2F92EE;'>#托泊替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54677, encryptionId=42cf546e792, topicName=托泊替康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Mon Jul 02 20:24:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292149, encodeId=12e8292149ff, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 02 06:25:09 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291817, encodeId=83de29181ea3, content=学习了.好文章., beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Mar 01 00:07:19 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361235, encodeId=808a136123524, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18366, encryptionId=1b63183668f, topicName=Veliparib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Feb 28 07:24:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379152, encodeId=311e13e9152d5, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Wed Feb 28 07:24:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291500, encodeId=d7232915007e, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Feb 28 00:08:40 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291126, encodeId=64d22911267f, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Feb 26 17:04:28 CST 2018, time=2018-02-26, status=1, ipAttribution=)]
2018-02-28 1e0f8808m18(暂无匿称)

学习了.谢谢分享.

62 0
[GetPortalCommentsPageByObjectIdResponse(id=1973230, encodeId=339119e3230d5, content=<a href='/topic/show?id=42cf546e792' target=_blank style='color:#2F92EE;'>#托泊替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54677, encryptionId=42cf546e792, topicName=托泊替康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Mon Jul 02 20:24:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292149, encodeId=12e8292149ff, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 02 06:25:09 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291817, encodeId=83de29181ea3, content=学习了.好文章., beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Mar 01 00:07:19 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361235, encodeId=808a136123524, content=<a href='/topic/show?id=1b63183668f' target=_blank style='color:#2F92EE;'>#Veliparib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18366, encryptionId=1b63183668f, topicName=Veliparib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Feb 28 07:24:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379152, encodeId=311e13e9152d5, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Wed Feb 28 07:24:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291500, encodeId=d7232915007e, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Feb 28 00:08:40 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291126, encodeId=64d22911267f, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Feb 26 17:04:28 CST 2018, time=2018-02-26, status=1, ipAttribution=)]
2018-02-26 1e0f8808m18(暂无匿称)

好文章.学习了.

44 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

CLIN CANCER RES：Veliparib联合托泊替康治疗实体肿瘤

相关资讯

科室

工具

服务